Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus chidamide in high-risk MDS after hypomethylating agent failure
ChiCTR2200061380Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax and tucidinostat in myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall response rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
venetoclaxtucidinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2200061380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061380.